Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 AMRI Breaks Ground on New Facility in India | Contract Pharma
Breaking News

AMRI Breaks Ground on New Facility in India

Albany Molecular Research, Inc. (AMRI) broke ground at the construction site of a new 50,000 sq.-ft. R&D center at the Shapoorji Pallonji Biotech Park in Hyderabad, India. The new facility represents the first major expansion of the company’s Hyderabad Research Center, a subsidiary of AMRI.

When completed in late 2007, the new R&D center will conduct contract projects in early stage drug discovery research, including custom chemical synthesis and medicinal chemistry. The new facility will also house a scale-up laboratory, which will be used to develop efficient methods for producing larger quantities of APIs and intermediates.

The new facility will add more than 100 employees to the company’s existing Hyderabad operations, which currently have 19 employees in the nearby ICICI Knowledge Park. The current facility can accommodate as many as 40 employees and is expected to reach full capacity in the coming months.

“The expansion of our Hyderabad Research Center will enhance our ability to provide customers with a range of flexible drug discovery and development services and cost options,” said AMRI chairman, chief executive officer and president, Thomas E. D’Ambra, Ph.D. “Since the opening of AMRI facilities in India and Singapore last year, many of our customers have already capitalized on the synergies created by this global expansion.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters